RecruitingPrimary Biliary Cholangitis

Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)

Eligible age

18–75 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

An Open Label Long-Term Study to Evaluate the Safety and Effectiveness of Fenofibrate in Subjects with Primary Biliary Cholangitis (PBC)

Sponsor: Xijing Hospital of Digestive Diseases

✓ Must have given written informed consent (signed and dated)
✓ Participated in the PBC study with fenofibrate (NCT02823353)
✓ Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose

✕ Treatment-related adverse event (AE) leading to fenofibrate discontinuation
✕ A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer)
✕ Known history of other liver diseases
✕ For females, pregnancy or breast-feeding
✕ Long-term use of immunosuppressive agents
✕ Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator

Source: ClinicalTrials.gov · NCT06365424 · last updated 2025-07-02